|Title||Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Gurka MJ, Guo Y, Filipp SL|
|Secondary Authors||DeBoer MD|
|Date Published||2018 01 19|
|Keywords||Biomarkers, Blood Glucose, Blood Pressure, Coronary Disease, Diabetes Mellitus, Type 2, Disease Progression, Female, Glycated Hemoglobin A, Humans, Lipids, Male, Metabolic Syndrome, Middle Aged, Prognosis, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, United States, Waist Circumference|
BACKGROUND: The severity of the metabolic syndrome (MetS) is significantly associated with future coronary heart disease (CHD) among individuals without baseline Type 2 diabetes. However, the validity of assessing MetS severity among individuals with diabetes is unknown.
OBJECTIVE: To assess for differences in MetS severity by timing of Type 2 diabetes diagnosis and to assess for associations between MetS severity and future CHD among individuals with diabetes.
METHODS: We analyzed data from participants of the Atherosclerosis Risk in Communities study, including 1419 with- and 7241 without diabetes, followed during 4 visits and adjudicated CHD diagnoses over a 20-year period. We used Cox-regression techniques to assess hazard ratios (HR) of CHD based on a sex- and race/ethnicity-specific MetS-severity Z-score (standard MetS score) and a similar MetS-severity score formulated without incorporating glucose as a component of MetS (no-glucose MetS score).
RESULTS: For both the standard- and no-glucose MetS-severity scores, scores were highest in the baseline-diabetes group, lowest in the never-diabetes group and intermediate in the incident-diabetes groups. Among participants with diabetes, increasing MetS-severity score at baseline was associated with incident CHD, using both the standard MetS score (HR 1.29, 95% confidence interval [CI] 1.21, 1.39) and the no-glucose score (HR 1.42, CI 1.24, 1.62) (both p
CONCLUSIONS: MetS severity appears to provide an estimate of metabolic disarray in the setting of diabetes and is predictive of future CHD events beyond HbA1c. Identifying MetS severity among individuals with diabetes may help in identifying those at higher risk, who could then receive further preventative treatment.
|Alternate Journal||Cardiovasc Diabetol|
|PubMed Central ID||PMC5775549|
|Grant List||HHSN268201700001I / HL / NHLBI NIH HHS / United States |
HHSN268201700004I / HL / NHLBI NIH HHS / United States
R01 HL120960 / HL / NHLBI NIH HHS / United States
HHSN268201000021C / HL / NHLBI NIH HHS / United States
HHSN268201700002I / HL / NHLBI NIH HHS / United States
HHSN268201700005I / HL / NHLBI NIH HHS / United States
HHSN268201700003I / HL / NHLBI NIH HHS / United States
1R01HL120960 / / National Heart, Lung, and Blood Institute (US) / International